Omalizumab
Warning: Array to string conversion in /home/clients/d0fa621b06e69d3a150fb7f06cec713f/vhost/sfdermato.org/reco/test/APP/worker/locale.php on line 37
Warning: Undefined variable $Array in /home/clients/d0fa621b06e69d3a150fb7f06cec713f/vhost/sfdermato.org/reco/test/APP/worker/locale.php on line 37
Warning: Trying to access array offset on null in /home/clients/d0fa621b06e69d3a150fb7f06cec713f/vhost/sfdermato.org/reco/test/APP/worker/locale.php on line 37
Warning: Array to string conversion in /home/clients/d0fa621b06e69d3a150fb7f06cec713f/vhost/sfdermato.org/reco/test/APP/worker/locale.php on line 37
Warning: Undefined variable $Array in /home/clients/d0fa621b06e69d3a150fb7f06cec713f/vhost/sfdermato.org/reco/test/APP/worker/locale.php on line 37
Warning: Trying to access array offset on null in /home/clients/d0fa621b06e69d3a150fb7f06cec713f/vhost/sfdermato.org/reco/test/APP/worker/locale.php on line 37
Warning: Array to string conversion in /home/clients/d0fa621b06e69d3a150fb7f06cec713f/vhost/sfdermato.org/reco/test/APP/worker/locale.php on line 37
Warning: Undefined variable $Array in /home/clients/d0fa621b06e69d3a150fb7f06cec713f/vhost/sfdermato.org/reco/test/APP/worker/locale.php on line 37
Warning: Trying to access array offset on null in /home/clients/d0fa621b06e69d3a150fb7f06cec713f/vhost/sfdermato.org/reco/test/APP/worker/locale.php on line 37
19/01/2026
Despite the low level of evidence, the working group recommends using omalizumab in cases of cold urticaria resistant to quadruple doses of anti-H1 antihistamines.
The working group recommends initially prescribing concomitant second-generation anti-H1 antihistamines at quadruple doses.
The recommended initial dose of omalizumab is 150 mg every 4 weeks. If there is no improvement after 12 weeks (UCT < 12/16), the dose can be increased to 300 mg every 4 weeks.
The working group reminds that omalizumab is only approved for chronic spontaneous urticaria from the age of 12.
The recommendations for the pediatric population are the same, although omalizumab is only approved for asthma from the age of 6 and for chronic spontaneous urticaria from the age of 12.
➜ Associated measures
